Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s):  ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


TSX:ATE - Post by User

Comment by MrMugsyon Oct 22, 2021 11:03am
219 Views
Post# 34037404

RE:RE:RE:RE:RE:How LTE suddenly became a cause of failure

RE:RE:RE:RE:RE:How LTE suddenly became a cause of failureI absolutely understand what you are saying about confirmation bias and people do need to keep it  in check.  That's true.

But ...

I look at the chronic pain dilemma a little differently than OTENA being done or being shutdown ... it's evolving.

We are presently waiting for the company to  come up with as a regimen to keep the liver enzymes in check while also ensuring enough painkiller in the process.

Let's just assume for a moment ... that with a lot of effort, they get close but not close enough for the regimen to ensure both - liver enzymes in check  - and -  enough painkilling. 

There is an additional angle that would need to be considered (if it isn't already).

Aside from throwing placebo in the mix as a viable dose in the regimen, we could also toss in naproxen pills (or another non-H2S suitable painkiller) into the toolbox.

Then - I see an enless set of combinations an permutations to get to the desired outcome and get us that balancing act that is needed.  Sure naproxen pills in the mix isn't ideal but with enough H2S in the system - it seems like a good last-ditch-effort.

So ...

While they figure out the pill order and the full regimen, chasing Acute makes perfect sense as it is faster and easier to the money (IMO).

--------------------

It's 2017 all over again - and I'm just fine watching the chaos.

Note:  I am not suggesting you buy or sell  shares - I'm giving you my angle and I'm looking for arguments that may indicate my thought process is wrong ... that's all.

: )
<< Previous
Bullboard Posts
Next >>